Seeking Alpha

More from the ASCO Oncology conference: Array BioPharma (ARRY) says its MEK162 selective...

More from the ASCO Oncology conference: Array BioPharma (ARRY) says its MEK162 selective inhibitor shows promising clinical activity in Phase ll trial in patients with NRAS mutated melanoma. Shares +2.5% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)